ImmusanT Raises $40 million to Support Development of Celiac Vaccine

According to a Press Release dated 14 November 2017, ImmusanT of Cambridge, MA received $40 million in financing to help fund their research into a therapeutic vaccine (Nexvax2) to treat Celiac.

Press Release – CAMBRIDGE, Mass. – November 14, 2017 – ImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine designed to induce immune tolerance in celiac disease, today announced the completion of a $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners. The proceeds will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. Nexvax2 will be studied as an adjunct to a gluten-free diet to demonstrate clinically relevant proof of concept for patients receiving a gluten challenge. Funds will also be used for the continued advancement of the company’s diagnostic biomarker program and platform expansion. Read entire Press Release here.

Media Contact:

George E. MacDougall

MacDougall Bioomedical Communications



Related Posts Plugin for WordPress, Blogger...

On December 7th, 2017, posted in: CeliacCorner Blogs by

Leave a comment - awaits moderation

Your email address will not be published. Required fields are marked *